Cargando…
Reducing Episodic Cluster Headaches: Focus on Galcanezumab
The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342329/ https://www.ncbi.nlm.nih.gov/pubmed/32753938 http://dx.doi.org/10.2147/JPR.S222604 |
_version_ | 1783555448694112256 |
---|---|
author | Pellesi, Lanfranco De Icco, Roberto Al-Karagholi, Mohammad Al-Mahdi Ashina, Messoud |
author_facet | Pellesi, Lanfranco De Icco, Roberto Al-Karagholi, Mohammad Al-Mahdi Ashina, Messoud |
author_sort | Pellesi, Lanfranco |
collection | PubMed |
description | The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache. |
format | Online Article Text |
id | pubmed-7342329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73423292020-08-03 Reducing Episodic Cluster Headaches: Focus on Galcanezumab Pellesi, Lanfranco De Icco, Roberto Al-Karagholi, Mohammad Al-Mahdi Ashina, Messoud J Pain Res Review The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache. Dove 2020-07-02 /pmc/articles/PMC7342329/ /pubmed/32753938 http://dx.doi.org/10.2147/JPR.S222604 Text en © 2020 Pellesi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Pellesi, Lanfranco De Icco, Roberto Al-Karagholi, Mohammad Al-Mahdi Ashina, Messoud Reducing Episodic Cluster Headaches: Focus on Galcanezumab |
title | Reducing Episodic Cluster Headaches: Focus on Galcanezumab |
title_full | Reducing Episodic Cluster Headaches: Focus on Galcanezumab |
title_fullStr | Reducing Episodic Cluster Headaches: Focus on Galcanezumab |
title_full_unstemmed | Reducing Episodic Cluster Headaches: Focus on Galcanezumab |
title_short | Reducing Episodic Cluster Headaches: Focus on Galcanezumab |
title_sort | reducing episodic cluster headaches: focus on galcanezumab |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342329/ https://www.ncbi.nlm.nih.gov/pubmed/32753938 http://dx.doi.org/10.2147/JPR.S222604 |
work_keys_str_mv | AT pellesilanfranco reducingepisodicclusterheadachesfocusongalcanezumab AT deiccoroberto reducingepisodicclusterheadachesfocusongalcanezumab AT alkaragholimohammadalmahdi reducingepisodicclusterheadachesfocusongalcanezumab AT ashinamessoud reducingepisodicclusterheadachesfocusongalcanezumab |